Bluebird Bio Inc (BLUE) - News Archive

Bluebird Bio Inc., a Nasdaq-listed company (BLUE), has encountered an unexpected twist in its corporate journey. The biotechnology firm received a formal notice on April 24, 2024 respectively from the Nasdaq Stock Marke...

In recent developments associated with listed biotechnology firms, bluebird bio, Inc., a leading expert in gene therapy, announced on April 24, 2024, that they had received an anticipatory notice from the Nasdaq Stock M...

Bluebird Bio Secures Debt Financing to Support Commercial Launches of Gene TherapiesBluebird Bio, a leading biotechnology company, has announced that it has secured a $175 million five-year term loan facility with Hercu...

Bluebird Bio Revolutionizes Treatment for Sickle Cell Disease with Outcomes-Based Agreement with MedicaidIn a groundbreaking move, bluebird bio, a biotechnology company based in Somerville, Massachusetts, has announced...

In a groundbreaking announcement, bluebird bio inc. presented updated data from its gene therapy program at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition. The data showcased the promising pot...

In a recent announcement, Bluebird Bio Inc., a biotechnology company based in Massachusetts, revealed promising data from their gene therapy program for the treatment of sickle cell disease. The results, presented at th...

The U.S-based biotech firm Bluebird Bio, Inc. has unveiled plans for the commercial launch of its groundbreaking LYFGENIA gene therapy, set to transform the management of sickle cell disease in a patient group aged 12 y...